Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47(Supplement 1):S2–6.
   PubMed Web of Science ®Google Scholar
• Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147(2):317–330.
   PubMed Web of Science ®Google Scholar
• Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Curr Epidemiol Rep. 2019;6(2):104–111.
   PubMedGoogle Scholar
• Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9(2):221–232.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Ozakyol A. Global Epidemiology of hepatocellular carcinoma (HCC Epidemiology). J Gastrointest Cancer. 2017;48(3):238–240.
   PubMed Web of Science ®Google Scholar
• Jain S, Thakkar N, Chhatai J, et al. Long non-coding RNA: functional agent for disease traits. RNA Biol. 2017;14(5):522–535.
   PubMed Web of Science ®Google Scholar
• Sanchez Calle A, Kawamura Y, Yamamoto Y, et al. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093–2100.
   PubMed Web of Science ®Google Scholar
• Rao AKDM, Rajkumar T, Mani S. Perspectives of long non-coding RNAs in cancer. Mol Biol Rep. 2017;44(2):203–218.
   PubMed Web of Science ®Google Scholar
• Mai H, Zhou B, Liu L, et al. Molecular pattern of lncRNAs in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):198.
   PubMed Web of Science ®Google Scholar
• Lim LJ, Wong SYS, Huang F, et al. Roles and regulation of long noncoding RNAs in hepatocellular carcinoma. Cancer Res. 2019;79(20):5131–5139.
   PubMed Web of Science ®Google Scholar
• Wang YG, Wang T, Shi M, et al. Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1. J Exp Clin Cancer Res. 2019;38(1):153.
   PubMed Web of Science ®Google Scholar
• Feng Y, Wei G, Zhang L, et al. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis. Bioengineered. 2021;12(1):8217–8232.
   PubMed Web of Science ®Google Scholar
• Chen JF, Wu P, Xia R, et al. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Cancer. 2018;17(1):6.
   PubMed Web of Science ®Google Scholar
• Chen Y, Shen T, Ding X, et al. HAGLROS is overexpressed and promotes non-small cell lung cancer migration and invasion. Jpn J Clin Oncol. 2020;50(9):1058–1067.
   PubMed Web of Science ®Google Scholar
• Yang M, Zhai Z, Zhang Y, et al. Clinical significance and oncogene function of long noncoding RNA HAGLROS overexpression in ovarian cancer. Arch Gynecol Obstet. 2019;300(3):703–710.
   PubMed Web of Science ®Google Scholar
• Zhou K, Xu J, Yin X, et al. Long noncoding RNA HAGLROS promotes cell invasion and metastasis by sponging mir-152 and upregulating ROCK1 expression in osteosarcoma. Comput Math Methods Med. 2020;2020:7236245.
   PubMed Web of Science ®Google Scholar
• Wei H, Hu J, Pu J, et al. Long noncoding RNA HAGLROS promotes cell proliferation, inhibits apoptosis and enhances autophagy via regulating miR-5095/ATG12 axis in hepatocellular carcinoma cells. Int Immunopharmacol. 2019;73:72–80.
   PubMed Web of Science ®Google Scholar
• López-Urrutia E, Bustamante Montes LP, Ladrón de Guevara Cervantes D, et al. Crosstalk between long non-coding RNAs, micro-RNAs and mRNAs: deciphering molecular mechanisms of master regulators in cancer. Front Oncol. 2019;9:669.
   PubMed Web of Science ®Google Scholar
• Han TS, Hur K, Cho HS, et al. Epigenetic associations between lncRNA/circRNA and miRNA in hepatocellular carcinoma. Cancers (Basel). 2020;12(9):2622.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Lin F, Gao L, Su Z, et al. Knockdown of KPNA2 inhibits autophagy in oral squamous cell carcinoma cell lines by blocking p53 nuclear translocation. Oncol Rep. 2018;40(1):179–194.
   PubMed Web of Science ®Google Scholar
• Shi C, Sun L, Liu S, et al. Overexpression of karyopherin subunit alpha 2 (KPNA2) predicts unfavorable prognosis and promotes bladder cancer tumorigenicity via the p53 pathway. Med Sci Monit. 2020;26:e921087.
   PubMed Web of Science ®Google Scholar
• Chen L, Dzakah EE, Shan G. Targetable long non-coding RNAs in cancer treatments. Cancer Lett. 2018;418:119–124.
   PubMed Web of Science ®Google Scholar
• Gutschner T, Richtig G, Haemmerle M, et al. From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer. Cancer Metastasis Rev. 2018;37(1):83–105.
   PubMed Web of Science ®Google Scholar
• Klingenberg M, Matsuda A, Diederichs S, et al. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67(3):603–618.
   PubMed Web of Science ®Google Scholar
• Liao HT, Huang JW, Lan T, et al. Identification of the aberrantly expressed lncRNAs in hepatocellular carcinoma: a bioinformatics analysis based on RNA-sequencing. Sci Rep. 2018;8(1):5395.
   PubMed Web of Science ®Google Scholar
• Shu L, Guo K, Lin ZH, et al. Long non-coding RNA HAGLROS promotes the development of diffuse large B-cell lymphoma via suppressing miR-100. J Clin Lab Anal. 2022;36(1):e24168.
   PubMed Web of Science ®Google Scholar
• Noh JH, Kim KM, McClusky WG, et al. Cytoplasmic functions of long noncoding RNAs. Wiley Interdiscip Rev RNA. 2018;9(3):e1471.
   PubMed Web of Science ®Google Scholar
• Zhou A, Chen G, Cheng X, et al. Inhibitory effects of miR‑26b‑5p on thyroid cancer. Mol Med Rep. 2019;20(2):1196–1202.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Seki N, Matsushita R, et al. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. Br J Cancer. 2016;115(3):354–363.
   PubMed Web of Science ®Google Scholar
• Jia CM, Tian YY, Quan LN, et al. miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. Pathol Res Pract. 2018;214(9):1388–1394.
   PubMed Web of Science ®Google Scholar
• Yi L, Liu Y, Xu A, et al. MicroRNA-26b-5p suppresses the proliferation of tongue squamous cell carcinoma via targeting proline rich 11 (PRR11). Bioengineered. 2021;12(1):5830–5838.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun B, Sun H, et al. Regulation of proliferation, angiogenesis and apoptosis in hepatocellular carcinoma by miR-26b-5p. Tumour Biol. 2016;37(8):10965–10979.
   PubMedGoogle Scholar
• Wang Y, Sun B, Zhao X, et al. Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma. Oncotarget. 2016;7(17):24383–24401.
   PubMedGoogle Scholar
• Han W, Li N, Liu J, et al. MicroRNA-26b-5p enhances T cell responses by targeting PIM-2 in hepatocellular carcinoma. Cell Signal. 2019;59:182–190.
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhu L. Interference of long non-coding RNA HAGLROS inhibits the proliferation and promotes the apoptosis of ovarian cancer cells by targeting miR-26b-5p. Exp Ther Med. 2021;22(2):879.
   PubMed Web of Science ®Google Scholar
• Han Y, Wang X. The emerging roles of KPNA2 in cancer. Life Sci. 2020;241:117140.
   PubMed Web of Science ®Google Scholar
• Christiansen A, Dyrskjøt L. The functional role of the novel biomarker karyopherin α 2 (KPNA2) in cancer. Cancer Lett. 2013;331(1):18–23.
   PubMed Web of Science ®Google Scholar
• Hua S, Ji Z, Quan Y, et al. Identification of hub genes in hepatocellular carcinoma using integrated bioinformatic analysis. Aging (Albany NY). 2020;12(6):5439–5468.
   PubMedGoogle Scholar
• Yang Y, Guo J, Hao Y, et al. Silencing of karyopherin α2 inhibits cell growth and survival in human hepatocellular carcinoma. Oncotarget. 2017;8(22):36289–36304.
   PubMedGoogle Scholar
• Guo X, Wang Z, Zhang J, et al. Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types. Acta Biochim Biophys Sin (Shanghai). 2019;51(3):285–292.
   PubMed Web of Science ®Google Scholar
• Niu F, Kazimierska M, Nolte IM, et al. The miR-26b-5p/KPNA2 axis is an important regulator of Burkitt lymphoma cell growth. Cancers (Basel). 2020;12(6):1464.
   PubMed Web of Science ®Google Scholar